This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Former Chinese Minister Of Health, Dr. Zhu Chen And "Father Of Targeted Therapy", Dr. Alex Matter, To Lead Joint Discussion On U.S. -- Asia Cancer Research Collaborations

Building Stronger Research Ties on Targeted Cancer Therapies at Top of Agenda

WASHINGTON, April 4, 2013 /PRNewswire-USNewswire/ -- Former Chinese Minister of Health and current Chairman of the Chinese Medical Association, Dr. Zhu Chen and Dr. Alex Matter, CEO, Experimental Therapeutics Centre, Agency of Science, Technology & Research of Singapore will hold meetings tomorrow to discuss the need for developing a stronger platform and broader collaborations in cancer research, particularly in area of targeted cancer therapies.  The meetings, co-hosted by the National Foundation for Cancer Research (NFCR) and the Asian Fund for Cancer Research (AFCR) and sponsored by the US Chinese Anti-Cancer Association (USCACA), will be held in Washington, DC and attended by renowned cancer experts from academic and industry research settings from both Asia and the US.   

Joining Dr. Chen and Dr. Matter in meetings and a panel discussion titled:  Targeted Cancer Therapies and Global Strategy for Clinical Development will be:
  • Dr. Sujuan Ba, President, Asian Fund for Cancer Research
  • Dr. Jan Buckner, Professor and Chair, Department of Oncology, Mayo Clinic
  • Dr. Xuetao Cao, President, Chinese Academy of Medical Science
  • Dr. Webster Cavenee,  Director, Ludwig Institute for Cancer Research, San Diego Branch
  • Dr. Xishan Hao,  President, Chinese Anti-Cancer Association and President of Tianjin Medical University Cancer Institute
  • Dr. Roy Jensen, Director, University of Kansas Cancer Center
  • Dr. Scott Patterson, Executive Director, Amgen
  • Dr. Peter Vogt, Professor, Scripps Research Institute
  • Li Yan, Managing Director, US Chinese Anti-Cancer Association

Targeted Cancer Therapy has become an increasingly popular option for cancer treatment because of its better therapeutic efficacy and fewer side effects over many standard chemotherapy drugs.  However, targeted cancer therapies are not free of side effects, and their efficacy is limited in many cases. 

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
TSLA $213.77 -3.90%
YHOO $36.99 2.80%
AAPL $92.93 -0.74%
FB $118.08 0.02%
GOOG $699.48 0.54%


Chart of I:DJI
DOW 17,686.02 +34.76 0.20%
S&P 500 2,053.44 +2.32 0.11%
NASDAQ 4,730.30 +4.6610 0.10%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs